• Home
  •  / Genomic Health

Genomic Health

OverviewSuggest Edit

Genomic Health, Inc. is the provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The Company is applying its scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring.
TypePublic
Founded2000
HQRedwood City, CA, USMap
Websitegenomichealth.com
Employee Ratings4More
Overall CultureB+More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)829(-3%)
Revenue (FY, 2018)$394.1 M(+16%)
Share Price (Nov 2019)$63.4
Cybersecurity ratingBMore

Key People/Management at Genomic Health

Jim Vaughn

Jim Vaughn

Chief U.S. Commercial Officer
Laura Leber

Laura Leber

Chief Communications Officer
Jason Radford

Jason Radford

Chief Legal Officer & Secretary
Ellen Beasley

Ellen Beasley

Senior Vice President, Products and Services R&D
Jon Cassel

Jon Cassel

Senior Vice President, Operations
Torsten Hoof

Torsten Hoof

Senior Vice President, International
Show more

Genomic Health Office Locations

Genomic Health has offices in Redwood City, Saint-Germain-en-Laye, Köln, Dublin 2 and in 3 other locations
Redwood City, CA, US (HQ)
101 Galveston Dr
Redwood City, CA, US
301 Penobscot Dr
Saint-Germain-en-Laye, FR
30 bis Rue du Vieil Abreuvoir
Köln, DE
Erna-Scheffler-Straße 1
Dublin 2, IE
70 Sir John Rogerson's Quay, Grand Canal Dock
Milano, IT
Piazza Filippo Meda, 3
Show all (9)

Genomic Health Financials and Metrics

Genomic Health Revenue

Genomic Health's revenue was reported to be $394.11 m in FY, 2018
USD

Revenue (Q3, 2019)

114.4m

Gross profit (Q3, 2019)

95.6m

Gross profit margin (Q3, 2019), %

83.6%

Net income (Q3, 2019)

18.7m

EBIT (Q3, 2019)

19.0m

Market capitalization (8-Nov-2019)

2.4b

Closing stock price (8-Nov-2019)

63.4

Cash (30-Sept-2019)

72.0m

EV

2.4b
Genomic Health's current market capitalization is $2.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

206.1m235.2m261.6m275.7m287.5m327.9m340.8m394.1m

Revenue growth, %

5%4%14%

Cost of goods sold

33.8m37.0m42.1m48.7m53.8m57.3m54.7m

Gross profit

172.3m198.2m219.5m227.0m233.7m270.6m286.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

50.8m52.1m58.5m57.6m58.6m63.1m63.7m66.0m67.0m70.5m69.1m68.2m70.6m73.6m80.9m82.0m82.3m84.0m85.5m83.8m92.6m95.6m101.3m108.8m114.1m114.4m

Cost of goods sold

8.2m9.2m9.3m9.0m9.0m9.7m10.8m10.8m12.1m12.2m12.0m12.8m13.0m13.7m15.8m15.2m13.7m13.8m13.4m18.7m14.4m15.5m17.0m17.7m18.7m

Gross profit

42.6m42.9m49.1m48.6m49.6m53.3m52.9m55.2m54.9m58.3m57.1m55.4m57.6m59.8m65.1m66.8m70.3m71.7m70.4m73.9m81.2m85.7m91.8m96.5m95.6m

Gross profit Margin, %

84%82%84%84%85%85%83%84%82%83%83%81%82%81%80%81%84%84%84%80%85%85%84%85%84%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

32.9m18.0m33.3m29.7m32.5m40.4m45.5m61.6m

Accounts Receivable

21.1m22.3m29.4m34.9m37.2m35.2m31.2m51.5m

Prepaid Expenses

7.4m8.9m10.2m9.9m10.8m13.5m13.5m

Inventories

13.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

23.8m38.3m37.0m57.0m58.0m17.1m32.8m39.8m28.2m32.5m37.2m22.9m23.8m28.0m30.7m40.7m34.0m40.8m42.2m43.0m42.1m53.8m69.2m101.4m90.9m72.0m

Accounts Receivable

19.4m22.6m20.8m21.7m19.9m27.0m26.7m25.6m28.9m31.8m31.0m35.0m32.9m33.8m38.8m33.6m33.7m34.6m32.4m35.6m46.6m49.0m51.6m59.2m54.3m55.9m

Prepaid Expenses

7.0m7.0m7.8m8.2m8.6m9.5m8.8m9.3m10.1m9.0m9.6m12.1m9.8m10.2m11.4m11.9m12.1m13.1m12.3m11.5m14.0m13.4m11.9m15.4m14.4m13.7m

Current Assets

87.4m108.2m130.4m142.5m154.8m132.6m142.7m149.0m139.9m146.5m145.2m175.0m162.4m142.0m136.6m139.0m144.3m142.1m154.5m166.1m191.0m215.4m246.7m280.7m312.2m345.0m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

7.8m8.2m(12.8m)(24.6m)(33.3m)(13.9m)(3.9m)25.7m

Depreciation and Amortization

7.3m5.5m6.3m6.9m7.1m8.9m11.8m12.7m

Accounts Payable

3.1m(2.1m)1.2m985.0k949.0k(4.6m)(2.3m)8.4m

Cash From Operating Activities

22.5m26.0m8.6m2.3m(11.8m)13.5m30.6m76.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

2.1m5.3m777.0k2.6m6.3m(883.0k)(3.9m)(3.4m)(7.4m)(12.1m)(18.3m)(9.5m)(18.7m)(30.6m)(6.4m)(12.5m)(15.3m)(806.0k)(3.5m)(5.7m)(3.8m)4.5m16.8m13.0m29.0m47.7m

Depreciation and Amortization

3.7m5.5m1.5m2.8m4.0m1.5m3.1m4.8m1.8m3.5m5.2m1.7m3.4m5.1m2.2m4.4m6.7m2.4m5.4m8.6m3.2m6.2m9.3m3.4m6.5m9.9m

Accounts Payable

(2.1m)(1.2m)(3.8m)(3.5m)(3.6m)(898.0k)(1.2m)(1.4m)2.4m292.0k672.0k239.0k(730.0k)(1.8m)(2.4m)(2.4m)(2.0m)2.2m2.2m5.7m4.6m4.7m5.9m(563.0k)(1.8m)(2.5m)

Cash From Operating Activities

3.6m10.7m2.3m8.4m19.7m(1.5m)4.7m12.7m126.0k2.1m2.6m(7.3m)(10.7m)(9.6m)(5.3m)1.8m10.6m765.0k11.9m21.5m6.3m22.2m52.0m(3.7m)34.7m66.9m
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Genomic Health Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

Genomic Health Online and Social Media Presence

Genomic Health's Trends

Embed Graph

Genomic Health Company Culture

  • Overall Culture

    B+

    73/100

  • CEO Rating

    A+

    84/100

  • Compensation

    B+

    79/100

  • Diversity

    B

    76/100

Learn more on Comparably

Genomic Health News and Updates

August 02, 2019

GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX

NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Genomic Health, Inc. (NasdaqGS: GHDX) to Exact Sciences Corp. (NasdaqGS: EXAS). Under the...
July 30, 2019

SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection with the proposed acquisition of the...
July 29, 2019

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Genomic Health, Inc. has obtained a Fair Price in its sale to Exact Sciences Corp.

MILWAUKEE, July 29, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Genomic (Nasdaq: GHDX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Genomic to Exact Sciences. Click here to learn how to join the action:...
July 29, 2019

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.
July 29, 2019

UPDATE 2-Diagnostic company Exact Sciences to buy Genomic Health in $2.8 bln deal

Exact Sciences Corp said on Monday it will buy peer Genomic Health Inc for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.
July 29, 2019

Exact Sciences to combine with Genomic Health in cash and stock deal valued at $2.8 billion

Molecular diagnostics company Exact Sciences Corp. and Genomic Health Inc. , which makes genomic-based diagnostic tests, said Monday they have agreed to combine in a deal valued at $2.8 billion. Under the terms of the deal, Exact Sciences will pay $72 per Genomic Health share in stock and cash. Th…
Show more

Genomic Health Blogs

November 07, 2019

Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences

Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences Content Import Thu, 11/07/2019 - 13:55 Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences November 7, 2019 at 1:55 PM EST This release is a backfill from a News …
September 30, 2019

New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment

New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment Content Import Mon, 09/30/2019 - 09:01 New TAILORx Data, Published Today in JAMA Oncology, Add to Strong E…
August 21, 2019

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer Content Import Wed, 08/21/2019 - 08:01 New St. Gallen International Breast Cancer Guidelines Recomme…
July 29, 2019

Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance

Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-Year 2019 Revenue and Net Income Guidance Earnings Call and Webcast Previously Scheduled for Thursday, August 1 Will Now Occur Today Monday,
July 29, 2019

Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company

Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
July 25, 2019

Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019

Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Content Import Thu, 07/25/2019 - 08:01 Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 …
Show more

 Genomic Health Frequently Asked Questions

  • When was Genomic Health founded?

    Genomic Health was founded in 2000.

  • Who are Genomic Health key executives?

    Genomic Health's key executives are Jim Vaughn, Laura Leber and Jason Radford.

  • How many employees does Genomic Health have?

    Genomic Health has 829 employees.

  • What is Genomic Health revenue?

    Latest Genomic Health annual revenue is $394.1 m.

  • What is Genomic Health revenue per employee?

    Latest Genomic Health revenue per employee is $475.4 k.

  • Who are Genomic Health competitors?

    Competitors of Genomic Health include Sophia Genetics, Tempus and Synthetic Genomics.

  • Where is Genomic Health headquarters?

    Genomic Health headquarters is located at 101 Galveston Dr, Redwood City.

  • Where are Genomic Health offices?

    Genomic Health has offices in Redwood City, Saint-Germain-en-Laye, Köln, Dublin 2 and in 3 other locations.

  • How many offices does Genomic Health have?

    Genomic Health has 9 offices.